← Back to Search
Bortezomib (Velcade): A First‐in‐Class Proteasome Inhibitor
Ben S Greener, David S. Millan
Published 2010 · Chemistry
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
This paper references
Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes1
H. Snyder (1958)
.alpha.-Chloro boronic esters from homologation of boronic esters
D. Matteson (1980)
Directed chiral synthesis with pinanediol boronic esters
D. Matteson (1980)
R-1-Acetamido-2-phenylethaneboronic acid. A specific transition-state analog for chymotrypsin
D. Matteson (1981)
Organoboranes. 30. Convenient procedures for the synthesis of alkyl- and alkenylboronic acids and esters
H. Brown (1983)
Epimerization of .alpha.-chloroboronic esters by lithium and zinc chlorides
D. Matteson (1983)
New coupling reagents in peptide chemistry
R. Knorr (1989)
Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome.
S. Tsubuki (1993)
Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors.
M. Bogyo (1997)
Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.
J. Adams (1998)
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
J. Adams (1999)
Bortezomib, a proteasome inhibitor, in cancer therapy: from concept to clinic
J. Albanell (2002)
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Richard A. Leblanc (2002)
The development of proteasome inhibitors as anticancer drugs.
J. Adams (2004)
A review of the proteasome inhibitor bortezomib in multiple myeloma
P. Richardson (2004)
The proteasome and proteasome inhibitors in cancer therapy.
P. Voorhees (2006)
Bortezomib for multiple myeloma
R. Popat (2006)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
D. Kuhn (2007)
Asymmetric copper-catalyzed synthesis of alpha-amino boronate esters from N-tert-butanesulfinyl aldimines.
M. A. Beenen (2008)
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Bruce D. Dorsey (2008)
Clinical development of novel proteasome inhibitors for cancer treatment
H. Yang (2009)
The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models
M. Williamson (2009)
Proteasome regulators: activators and inhibitors.
L. Huang (2009)
A convergent approach to synthesis of bortezomib: the use of TBTU suppresses racemization in the fragment condensation
A. S. Ivanov (2009)
This paper is referenced by
Key Metrics to Inform Chemical Synthesis Route Design
J. Andraos (2018)
Exploiting the Bis-Nucleophilicity of α-Aminoboronates: Copper-Catalyzed, Intramolecular Aminoalkylations of Bromobenzoyl Chlorides.
A. Dumas (2016)
Air- and moisture-stable amphoteric molecules: enabling reagents in synthesis.
Zhi He (2014)
α-Boryl isocyanides enable facile preparation of bioactive boropeptides.
Adam Zajdlik (2013)